CVS Health (CVS) Reaches Global Opioid Settlement, Will Pay $5B Over 10 Years
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
'Several De-Risking Events Positive' for CVS Health (CVS) - Mizuho
November 2, 2022 12:58 PM EDTMizuho Securities analyst Ann Hynes reiterated a Buy rating and $120.00 price target on CVS Health (NYSE: CVS) following Q3 results as several de-risking events are positive for the stock.
The analyst commented, "CVS announced 1) good Q3:22 earnings, 2) provided 2023 initial 2023 EPS guidance of -3.5%... More
